by Jakub Jarolím, Business Intelligence Department
Dear customer, we are sorry but your browser doesn't support all necessary features for good site view. Please switch to one of the modern browsers (Chrome, Safari, Firefox).
Sotio Biotech
2/5/2021
April 2021 Review of news from the most innovative therapeutic areas and the business development transactions
SOTIO
Market
The Nasdaq Biotech Index added 4 % during April 2021
The Nasdaq Biotech Index added 4 % during April after a drop experienced in March. The index is however still 10 % below its maximum from February this year. Numerous companies presented their new data during virtual AACR conference.
Prostate Cancer
Nivolumab-ipilimumab combo demonstrated significant antitumor activity in PCA
Nivolumab-ipilimumab combination demonstrates antitumor activity in prostate cancer subset. A combination of nivolumab and ipilimumab induced significant antitumor activity among men with metastatic castration-resistant prostate cancer and a positive immunogenic signature, according to results of the phase 2 NEPTUNES trial.
Ovarian Cancer News
Merck and Alkermes to evaluate combination of Keytruda with nemvaleukin
FDA approved theinitiation of endoxifenstudy in OVCA. A patient with ovarian cancer has begun treatment with oral endoxifen, an active metabolite of tamoxifen, after a Safe to Proceed Letter was granted by the FDA, according to a press release by Atossa Therapeutics.
Lung Cancer News
AstraZeneca’s Tagrisso was approved in China for lung cancer treatment
AstraZeneca's lung cancer drug approved in China: AstraZeneca said that its Tagrisso medicine has been approved in China for the treatment of early lung cancer. The UK-based pharmaceutical giant said Tagrisso is the first such drug to have received approval in China, as well as the only one to have shown efficacy against the disease in a global trial.
Share on social networks